Merck's Welireg wins label expansion in kidney cancer despite missing survival data
Merck’s Welireg won a label expansion on Thursday in a common form of kidney cancer, weeks ahead of its decision date and without a clear …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
